Predischarge and Postdischarge Heart Failure Management: Treatment Optimisation, Adherence, and Multidisciplinary Care
Main Article Content
Abstract
Hospitalisation for heart failure presents a critical event associated with significant risk of readmission and mortality. It also offers a window of opportunity to optimise patient management with a goal to improve clinical outcomes, functional status, and quality of life. This narrative review summarises contemporary, evidence-based strategies for optimising heart failure management before and after hospital discharge. Firstly, comprehensive assessment of congestion status is necessary before discharge because residual congestion is a major contributor to poor outcomes. In addition, robust evidence supports the early initiation and rapid up-titration of core guideline-directed medical therapies in all patients without known contraindications, irrespective of left ventricular ejection fraction. The core guideline-directed medical therapies classes include renin-angiotensin system inhibitors, sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. Intensive strategy to optimisation of renin-angiotensin system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists has been shown to reduce the risk of death or readmission by 34% at six months compared to standard care. Likewise, initiating sodium-glucose cotransporter-2 inhibitors during hospitalisation has demonstrated favourable effects on clinical outcomes, including lower risk of all-cause mortality and readmission. Furthermore, multidisciplinary care and early and sustained postdischarge follow-up are essential to address comorbidities, ensure continuity of care and allow further optimisation of medical therapy. They also enable timely management of potential issues concerning drug intolerance, side effects, nonadherence, or changes in clinical status. Successful long-term management and adherence to treatment recommendations also requires structured patient education and empowerment for self-care.
Keywords:
heart failure, management, guideline-directed medical therapy, congestion, adherence, multidisciplinary care, education
Article Details
How to Cite
POLOVINA, Marija et al.
Predischarge and Postdischarge Heart Failure Management: Treatment Optimisation, Adherence, and Multidisciplinary Care.
Medical Research Archives, [S.l.], v. 13, n. 5, may 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6550>. Date accessed: 21 june 2025.
doi: https://doi.org/10.18103/mra.v13i5.6550.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. Nov 10 2018;392(10159):1789-1858. doi:10.1016/s0140-6736(18)32279-7
2. Seferović PM, Vardas P, Jankowska EA, et al. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. Eur J Heart Fail. Jun 2021;23(6):906-914. doi:10.1002/ejhf.2143
3. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. Apr 2015;12(4):220-9. doi:10.1038/nrcardio.2015.14
4. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. Sep 21 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
5. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195
6. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. Dec 3 2022;400(10367):1938-1952. doi:10.1016/s0140-6736(22)02076-1
7. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine. 2022/03/01 2022;28(3):568 -574. doi:10.1038/s41591-021-01659-1
8. Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology. 2022;80(14):1302-1310. doi:doi:10.1016/j.jacc.2022.07.021
9. Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status-impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. Nov 2019;21(11):1338-1352. doi:10.1002/ejhf.1492
10. Malgie J, Wilde MI, Clephas PRD, et al. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study. European Journal of Heart Failure. 2024;26(7):1549-1560. doi:https://doi.org/10.1002/ejhf.3267
11. Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure WithReduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. Jul 24 2018;72(4):351-366. doi:10.1016/j.jacc.2018.04.070
12. Biegus J, Cotter G, Davison BA, et al. The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial. J Card Fail. Feb 2025;31(2):354-366. doi:10.1016/j.cardfail.2024.09.002
13. Martens P, Nijst P, Mullens W. Current Approach to Decongestive Therapy in Acute Heart Failure. Curr Heart Fail Rep. Dec 2015;12(6):367-78. doi:10.1007/s11897-015-0273-5
14. Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. Mar 2013;34(11):835-43. doi:10.1093/eurheartj/ehs444
15. Pagnesi M, Staal L, Ter Maaten JM, et al. Decongestion and Outcomes in Patients Hospitalized for Acute HeartFailure: Insights From the RELAX-AHF-2 Trial. JACC Heart Fail. Mar 2025;13(3):414-429. doi:10.1016/j.jchf.2024.09.013
16. Odajima S, Fujimoto W, Kuroda K, et al. Association of congestion with worsening renal function in acute decompensated heart failure according to age. ESC Heart Fail. Dec 2022;9(6):4250-4261. doi:10.1002/ehf2.14157
17. Chioncel O, Benson L, Crespo-Leiro MG, et al. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry. Eur J Prev Cardiol. Sep 20 2023;30(13):1346-1358. doi:10.1093/eurjpc/zwad151
18. Metra M, Adamo M, Tomasoni D, et al. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. Eur J Heart Fail. Jul 2023;25(7):1115-1131. doi:10.1002/ejhf.2888
19. Salah K, Kok WE, Eurlings LW, et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart. Jan 2014;100(2):115-25. doi:10.1136/heartjnl-2013-303632
20. Núñez J, Llàcer P, García-Blas S, et al. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. Am J Med. Mar 2020;133(3):370-380.e4. doi:10.1016/j.amjmed.2019.07.041
21. Feola M, Testa M, Ferreri C, et al. Role of Response-to-Diuretic in Predicting Prognosis in Discharged Heart Failure Patients After an Acute Decompensation. Archives of Medical Research. 2018/04/01/ 2018;49(3):198-204. doi:https://doi.org/10.1016/j.arcmed.2018.08.007
22. Chen Y, Ji X-w, Zhang A-y, Lv J-c, Zhang J-g, Zhao C-h. Prognostic Value of Plasma Ghrelin in Predicting the Outcome of Patients with Chronic Heart Failure. Archives of Medical Research. 2014/04/01/ 2014;45(3):263-269. doi:https://doi.org/10.1016/j.arcmed.2014.01.004
23. Collins SP, Lindsell CJ, Storrow AB, Abraham WT. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med. Jan 2006;47(1):13-8. doi:10.1016/j.annemergmed.2005.04.003
24. Kobayashi M, Watanabe M, Coiro S, et al. Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. Int J Cardiol. Aug 15 2019;289:91-98. doi:10.1016/j.ijcard.2019.01.091
25. Thavendiranathan P, Yingchoncharoen T, Grant A, et al. Prediction of 30-day heart failure-specific readmission risk by echocardiographic parameters. Am J Cardiol. Jan 15 2014;113(2):335-41. doi:10.1016/j.amjcard.2013.09.025
26. Öhman J, Harjola VP, Karjalainen P, Lassus J. Assessment of early treatment response by rapid cardiothoracic ultrasound in acute heart failure: Cardiac filling pressures, pulmonary congestion and mortality. Eur Heart J Acute Cardiovasc Care. Jun 2018;7(4):311-320. doi:10.1177/2048872617708974
27. Goonewardena SN, Gemignani A, Ronan A, et al. Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. JACC Cardiovasc Imaging. Sep 2008;1(5):595-601. doi:10.1016/j.jcmg.2008.06.005
28. Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J. Jul 14 2016;37(27):2097-104. doi:10.1093/eurheartj/ehw164
29. Coiro S, Rossignol P, Ambrosio G, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. Nov 2015;17(11):1172-81. doi:10.1002/ejhf.344
30. Gargani L, Pang PS, Frassi F, et al. Persistent pulmonary congestion before discharge predicts rehospitalization in heart failure: a lung ultrasound study. Cardiovasc Ultrasound. Sep 4 2015;13:40. doi:10.1186/s12947-015-0033-4
31. Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. Sep 29 2022;387(13): 1185-1195. doi:10.1056/NEJMoa2203094
32. Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. European Heart Journal. 2022;44(5):411-421. doi:10.1093/eurheartj/ehac689
33. ter Maaten JM, Beldhuis IE, van der Meer P, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nature Medicine. 2023/10/01 2023;29(10):2625-2632. doi:10.1038/s41591-023-02532-z
34. Palin V, Drozd M, Garland E, et al. Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes. ESC Heart Fail. Oct 2022;9(5):3298-3307. doi:10.1002/ehf2.14051
35. Kimmoun A, Cotter G, Davison B, et al. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Eur J Heart Fail. Nov 2019;21(11):1459-1467. doi:10.1002/ejhf.1575
36. Biegus J, Mebazaa A, Davison B, et al. Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF. J Am Coll Cardiol. Jul 23 2024;84(4):323-336. doi:10.1016/j.jacc.2024.04.055
37. Čelutkienė J, Čerlinskaitė-Bajorė K, Cotter G, et al. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial. Circ Heart Fail. Apr 2024;17(4):e011221. doi:10.1161/circheartfailure.123.011221
38. Adamo M, Pagnesi M, Mebazaa A, et al. NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial. Eur Heart J. Aug 14 2023;44(31):2947-2962. doi:10.1093/eurheartj/ehad335
39. Biegus J, Voors AA, Collins SP, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. Jan 1 2023;44(1):41-50. doi:10.1093/eurheartj/ehac530
40. Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. Mar 2019;21(3):337-341. doi:10.1002/ejhf.1402
41. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. Oct 24 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107
42. Vaduganathan M, Claggett BL, Desai AS, et al. Time to Significant Benefit of Finerenone in Patients With HeartFailure. Journal of the American College of Cardiology. 2025/01/21/ 2025;85(2):199-202. doi:https://doi.org/10.1016/j.jacc.2024.09.018
43. Vaduganathan M, Claggett BL, Jhund P, et al. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiology. 2022;7(12):1259-1263. doi:10.1001/jamacardio.2022.3750
44. Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. May 10 2011;57(19):1899-907. doi:10.1016/j.jacc.2010.11.057
45. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. May 5 2004;43(9):1534-41. doi:10.1016/j.jacc.2003.12.040
46. Sanam K, Bhatia V, Bajaj NS, et al. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure. Am J Med. Oct 2016;129(10):1067-73. doi:10.1016/j.amjmed.2016.05.008
47. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. Feb 7 2019;380(6):539-548. doi:10.1056/NEJMoa1812851
48. Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. Aug 2019;21(8):998-1007. doi:10.1002/ejhf.1498
49. Berg DD, Braunwald E, DeVore AD, et al. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail. Oct 2020;8(10):834-843. doi:10.1016/j.jchf.2020.06.008
50. Fonarow GC, Abraham WT, Albert NM, et al. Prospective Evaluation of Beta-Blocker Use at the Time of Hospital Discharge as a Heart Failure Performance Measure: Results From OPTIMIZE-HF. Journal of Cardiac Failure. 2007;13(9):722-731. doi:10.1016/j.cardfail.2007.06.727
51. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. Jul 15 2008;52(3):190-9. doi:10.1016/j.jacc.2008.03.048
52. Lee KK, Yang J, Hernandez AF, Steimle AE, Go AS. Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. Med Care. Apr 2016;54(4):365-72. doi:10.1097/mlr.0000000000000492
53. McAlister FA, Youngson E, Kaul P, Ezekowitz JA. Early Follow-Up After a Heart Failure Exacerbation: The Importance of Continuity. Circ Heart Fail. Sep 2016;9(9)doi:10.1161/circheartfailure.116.003194
54. Savarese G, Lund LH, Dahlström U, Strömberg A. Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization. J Am Heart Assoc. May 21 2019;8(10):e011737. doi:10.1161/jaha.118.011737
55. Logeart D, Berthelot E, Bihry N, et al. Early and short-term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD-HF). European Journal of Heart Failure. 2022;24(1):219-226. doi:https://doi.org/10.1002/ejhf.2357
56. Savarese G, Kishi T, Vardeny O, et al. HeartFailure Drug Treatment-Inertia,Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC: Heart Failure. 2023/01/01/ 2023;11(1):1-14. doi:https://doi.org/10.1016/j.jchf.2022.08.009
57. Tomasoni D, Pagnesi M, Colombo G, et al. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Eur J Heart Fail. Feb 2024;26(2):327-337. doi:10.1002/ejhf.3081
58. Seferović PM, Polovina M, Adlbrecht C, et al. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. Eur J Heart Fail. Dec 2021;23(12):1999-2007. doi:10.1002/ejhf.2378
59. Khan MS, Segar MW, Usman MS, et al. Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial. JACC Heart Fail. Apr 2022;10(4):266-275. doi:10.1016/j.jchf.2021.12.004
60. Arrigo M, Biegus J, Asakage A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: A sub-analysis of the STRONG-HF randomized clinical trial. Eur J Heart Fail. Jul 2023;25(7):1145-1155. doi:10.1002/ejhf.2920
61. Savarese G, Lindberg F, Christodorescu RM, et al. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice. European Journal of Heart Failure. 2024;26(6):1408-1418. doi:https://doi.org/10.1002/ejhf.3214
62. Jalloh MB, Granger CB, Fonarow GC, Van Spall HGC. Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure. Eur Heart J. Jun 20 2023;44(23):2055-2058. doi:10.1093/eurheartj/ehad150
63. van der Wal MH, Jaarsma T, van Veldhuisen DJ. Non-compliance in patients with heart failure; how can we manage it? Eur J Heart Fail. Jan 2005;7(1):5-17. doi:10.1016/j.ejheart.2004.04.007
64. Jonkman NH, Westland H, Groenwold RH, et al. What Are Effective Program Characteristics of Self-Management Interventions in Patients With Heart Failure? An Individual Patient Data Meta-analysis. J Card Fail. Nov 2016;22(11):861-871. doi:10.1016/j.cardfail.2016.06.422
65. Unverzagt S, Meyer G, Mittmann S, Samos FA, Unverzagt M, Prondzinsky R. Improving Treatment Adherence in Heart Failure. Dtsch Arztebl Int. Jun 24 2016;113(25):423-30. doi:10.3238/arztebl.2016.0423
66. Wang L, Zhao Y, Han L, et al. Pharmacist-Led Management Model and Medication Adherence Among Patients With Chronic Heart Failure: A Randomized Clinical Trial. JAMA Netw Open. Dec 2 2024;7(12):e2453976. doi:10.1001/jamanetworkopen.2024.53976
67. Goldstein CM, Gathright EC, Dolansky MA, et al. Randomized controlled feasibility trial of two telemedicine medication reminder systems for older adults with heart failure. J Telemed Telecare. Sep 2014;20(6):293-9. doi:10.1177/1357633x14541039
68. Stolfo D, Iacoviello M, Chioncel O, et al. How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. European Journal of Heart Failure. n/a(n/a)doi:https://doi.org/10.1002/ejhf.3642
69. Pandey A, Keshvani N, Wang TJ. Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction? Circulation. 2022;146(4):276-278. doi:doi:10.1161/CIRCULATIONAHA.122.059661
70. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta-Analysis of Controlled Trials. J Am Heart Assoc. Jun 17 2016;5(6)doi:10.1161/jaha.115.002606
71. Tomasoni D, Vitale C, Guidetti F, et al. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. Apr 2024;26(4):854-868. doi:10.1002/ejhf.3112
72. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: A systematic review and meta-analysis. Int J Cardiol. Jun 1 2017;236:283-289. doi:10.1016/j.ijcard.2017.01.153
73. Seferović PM, Piepoli MF, Lopatin Y, et al. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. Eur J Heart Fail. May 2020;22(5):763-774. doi:10.1002/ejhf.1784
74. Bonilla-Palomas JL, Gámez-López AL, Castillo-Domínguez JC, et al. Nutritional Intervention in Malnourished Hospitalized Patients with Heart Failure. Archives of Medical Research. 2016/10/01/ 2016;47(7):535-540. doi:https://doi.org/10.1016/j.arcmed.2016.11.005
75. Holland R, Battersby J, Harvey I, Lenaghan E, Smith J, Hay L. Systematic review of multidisciplinary interventions in heart failure. Heart. Jul 2005;91(7):899-906. doi:10.1136/hrt.2004.048389
76. Kitzman DW, Whellan DJ, Duncan P, et al. Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. N Engl J Med. Jul 15 2021;385(3):203-216. doi:10.1056/NEJMoa2026141
77. Nadruz W, Jr., West E, Sengeløv M, et al. Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. J Am Heart Assoc. Oct 31 2017;6(11)doi:10.1161/jaha.117.006000
78. Swank AM, Horton J, Fleg JL, et al. Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. Circ Heart Fail. Sep 1 2012;5(5):579-85. doi:10.1161/circheartfailure.111.965186
79. Resurrección DM, Moreno-Peral P, Gómez-Herranz M, et al. Factors associated with non-participation in and dropout from cardiac rehabilitation programmes: a systematic review of prospective cohort studies. Eur J Cardiovasc Nurs. Jan 2019;18(1):38-47. doi:10.1177/1474515118783157
80. Lee CS, Bidwell JT, Paturzo M, et al. Patterns of self-care and clinical events in a cohort of adults with heart failure: 1 year follow-up. Heart Lung. Jan-Feb 2018;47(1):40-46. doi:10.1016/j.hrtlng.2017.09.004
81. Jaarsma T, Hill L, Bayes-Genis A, et al. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. Jan 2021;23(1):157-174. doi:10.1002/ejhf.2008
82. Park JJ, Kim S-H, Oh I-Y, et al. The Effect of Door-to-Diuretic Time on Clinical Outcomes in PatientsWithAcute Heart Failure. JACC: Heart Failure. 2018;6(4):286-294. doi:doi:10.1016/j.jchf.2017.12.017
83. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. Mar 3 2011;364(9):797-805. doi:10.1056/NEJMoa1005419
84. Butler J, Anstrom KJ, Felker GM, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol. Sep 1 2017;2(9):950-958. doi:10.1001/jamacardio.2017.2198
85. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome Trial. JAMA. 2007;297(12):1319-1331. doi:10.1001/jama.297.12.1319
86. Costanzo MR, Ronco C, Abraham WT, et al. Extracorporeal Ultrafiltration for FluidOverload in Heart Failure: Current Status and Prospects for Further Research. Journal of the American College of Cardiology. 2017/05/16/ 2017;69(19):2428-2445. doi:https://doi.org/10.1016/j.jacc.2017.03.528
87. Bhatt AS, Varshney AS, Moscone A, et al. Virtual Care Team Guided Management of Patients With Heart Failure DuringHospitalization. J Am Coll Cardiol. May 2 2023;81(17):1680-1693. doi:10.1016/j.jacc.2023.02.029
88. Rao VN, Shah A, McDermott J, et al. In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial. Circ Heart Fail. Feb 2023;16(2):e010158. doi:10.1161/circheartfailure.122.010158
89. Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. Sep 22 2018;392(10152):1047-1057. doi:10.1016/s0140-6736(18)31880-4
90. Wong CK, Un KC, Zhou M, et al. Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study. Eur Heart J Digit Health. Jun 2022;3(2):284-295. doi:10.1093/ehjdh/ztac024
91. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. Jun 24 2023;401(10394):2113-2123. doi:10.1016/s0140-6736(23)00923-6
92. Ghazi L, Yamamoto Y, Riello RJ, et al. Electronic Alerts to Improve HeartFailure Therapy in Outpatient Practice: AClusterRandomized Trial. J Am Coll Cardiol. Jun 7 2022;79(22):2203-2213. doi:10.1016/j.jacc.2022.03.338
93. Allen LA, Venechuk G, McIlvennan CK, et al. An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial. Circulation. Feb 2 2021;143(5):427-437. doi:10.1161/circulationaha.120.051863
94. Janse RJ, Fu EL, Dahlström U, et al. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence. European Journal of Heart Failure. 2022;24(11):2185-2195. doi:https://doi.org/10.1002/ejhf.2620
95. Granger BB, Ekman I, Granger CB, et al. Adherence to medication according to sex and age in the CHARM programme. European Journal of Heart Failure. 2009;11(11):1092-1098. doi:https://doi.org/10.1093/eurjhf/hfp142
96. Aggarwal B, Pender A, Mosca L, Mochari-Greenberger H. Factors associated with medication adherence among heart failure patients and their caregivers. J Nurs Educ Pract. 2015;5(3):22-27. doi:10.5430/jnep.v5n3p22
97. Gunnthorsdottir I, Almarsdottir AB, Andersen K, et al. Factors Influencing Medication Adherence in Heart Failure Patients—A Survey Among Cardiac Healthcare Providers. Clinical Pharmacology & Therapeutics. 2025;117(4):1088-1097. doi:https://doi.org/10.1002/cpt.3526
2. Seferović PM, Vardas P, Jankowska EA, et al. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. Eur J Heart Fail. Jun 2021;23(6):906-914. doi:10.1002/ejhf.2143
3. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. Apr 2015;12(4):220-9. doi:10.1038/nrcardio.2015.14
4. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. Sep 21 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
5. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195
6. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. Dec 3 2022;400(10367):1938-1952. doi:10.1016/s0140-6736(22)02076-1
7. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine. 2022/03/01 2022;28(3):568 -574. doi:10.1038/s41591-021-01659-1
8. Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology. 2022;80(14):1302-1310. doi:doi:10.1016/j.jacc.2022.07.021
9. Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status-impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. Nov 2019;21(11):1338-1352. doi:10.1002/ejhf.1492
10. Malgie J, Wilde MI, Clephas PRD, et al. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study. European Journal of Heart Failure. 2024;26(7):1549-1560. doi:https://doi.org/10.1002/ejhf.3267
11. Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure WithReduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. Jul 24 2018;72(4):351-366. doi:10.1016/j.jacc.2018.04.070
12. Biegus J, Cotter G, Davison BA, et al. The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial. J Card Fail. Feb 2025;31(2):354-366. doi:10.1016/j.cardfail.2024.09.002
13. Martens P, Nijst P, Mullens W. Current Approach to Decongestive Therapy in Acute Heart Failure. Curr Heart Fail Rep. Dec 2015;12(6):367-78. doi:10.1007/s11897-015-0273-5
14. Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. Mar 2013;34(11):835-43. doi:10.1093/eurheartj/ehs444
15. Pagnesi M, Staal L, Ter Maaten JM, et al. Decongestion and Outcomes in Patients Hospitalized for Acute HeartFailure: Insights From the RELAX-AHF-2 Trial. JACC Heart Fail. Mar 2025;13(3):414-429. doi:10.1016/j.jchf.2024.09.013
16. Odajima S, Fujimoto W, Kuroda K, et al. Association of congestion with worsening renal function in acute decompensated heart failure according to age. ESC Heart Fail. Dec 2022;9(6):4250-4261. doi:10.1002/ehf2.14157
17. Chioncel O, Benson L, Crespo-Leiro MG, et al. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry. Eur J Prev Cardiol. Sep 20 2023;30(13):1346-1358. doi:10.1093/eurjpc/zwad151
18. Metra M, Adamo M, Tomasoni D, et al. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. Eur J Heart Fail. Jul 2023;25(7):1115-1131. doi:10.1002/ejhf.2888
19. Salah K, Kok WE, Eurlings LW, et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart. Jan 2014;100(2):115-25. doi:10.1136/heartjnl-2013-303632
20. Núñez J, Llàcer P, García-Blas S, et al. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. Am J Med. Mar 2020;133(3):370-380.e4. doi:10.1016/j.amjmed.2019.07.041
21. Feola M, Testa M, Ferreri C, et al. Role of Response-to-Diuretic in Predicting Prognosis in Discharged Heart Failure Patients After an Acute Decompensation. Archives of Medical Research. 2018/04/01/ 2018;49(3):198-204. doi:https://doi.org/10.1016/j.arcmed.2018.08.007
22. Chen Y, Ji X-w, Zhang A-y, Lv J-c, Zhang J-g, Zhao C-h. Prognostic Value of Plasma Ghrelin in Predicting the Outcome of Patients with Chronic Heart Failure. Archives of Medical Research. 2014/04/01/ 2014;45(3):263-269. doi:https://doi.org/10.1016/j.arcmed.2014.01.004
23. Collins SP, Lindsell CJ, Storrow AB, Abraham WT. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med. Jan 2006;47(1):13-8. doi:10.1016/j.annemergmed.2005.04.003
24. Kobayashi M, Watanabe M, Coiro S, et al. Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. Int J Cardiol. Aug 15 2019;289:91-98. doi:10.1016/j.ijcard.2019.01.091
25. Thavendiranathan P, Yingchoncharoen T, Grant A, et al. Prediction of 30-day heart failure-specific readmission risk by echocardiographic parameters. Am J Cardiol. Jan 15 2014;113(2):335-41. doi:10.1016/j.amjcard.2013.09.025
26. Öhman J, Harjola VP, Karjalainen P, Lassus J. Assessment of early treatment response by rapid cardiothoracic ultrasound in acute heart failure: Cardiac filling pressures, pulmonary congestion and mortality. Eur Heart J Acute Cardiovasc Care. Jun 2018;7(4):311-320. doi:10.1177/2048872617708974
27. Goonewardena SN, Gemignani A, Ronan A, et al. Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. JACC Cardiovasc Imaging. Sep 2008;1(5):595-601. doi:10.1016/j.jcmg.2008.06.005
28. Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J. Jul 14 2016;37(27):2097-104. doi:10.1093/eurheartj/ehw164
29. Coiro S, Rossignol P, Ambrosio G, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. Nov 2015;17(11):1172-81. doi:10.1002/ejhf.344
30. Gargani L, Pang PS, Frassi F, et al. Persistent pulmonary congestion before discharge predicts rehospitalization in heart failure: a lung ultrasound study. Cardiovasc Ultrasound. Sep 4 2015;13:40. doi:10.1186/s12947-015-0033-4
31. Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. Sep 29 2022;387(13): 1185-1195. doi:10.1056/NEJMoa2203094
32. Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. European Heart Journal. 2022;44(5):411-421. doi:10.1093/eurheartj/ehac689
33. ter Maaten JM, Beldhuis IE, van der Meer P, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nature Medicine. 2023/10/01 2023;29(10):2625-2632. doi:10.1038/s41591-023-02532-z
34. Palin V, Drozd M, Garland E, et al. Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes. ESC Heart Fail. Oct 2022;9(5):3298-3307. doi:10.1002/ehf2.14051
35. Kimmoun A, Cotter G, Davison B, et al. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Eur J Heart Fail. Nov 2019;21(11):1459-1467. doi:10.1002/ejhf.1575
36. Biegus J, Mebazaa A, Davison B, et al. Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF. J Am Coll Cardiol. Jul 23 2024;84(4):323-336. doi:10.1016/j.jacc.2024.04.055
37. Čelutkienė J, Čerlinskaitė-Bajorė K, Cotter G, et al. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial. Circ Heart Fail. Apr 2024;17(4):e011221. doi:10.1161/circheartfailure.123.011221
38. Adamo M, Pagnesi M, Mebazaa A, et al. NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial. Eur Heart J. Aug 14 2023;44(31):2947-2962. doi:10.1093/eurheartj/ehad335
39. Biegus J, Voors AA, Collins SP, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. Jan 1 2023;44(1):41-50. doi:10.1093/eurheartj/ehac530
40. Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. Mar 2019;21(3):337-341. doi:10.1002/ejhf.1402
41. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. Oct 24 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107
42. Vaduganathan M, Claggett BL, Desai AS, et al. Time to Significant Benefit of Finerenone in Patients With HeartFailure. Journal of the American College of Cardiology. 2025/01/21/ 2025;85(2):199-202. doi:https://doi.org/10.1016/j.jacc.2024.09.018
43. Vaduganathan M, Claggett BL, Jhund P, et al. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiology. 2022;7(12):1259-1263. doi:10.1001/jamacardio.2022.3750
44. Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. May 10 2011;57(19):1899-907. doi:10.1016/j.jacc.2010.11.057
45. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. May 5 2004;43(9):1534-41. doi:10.1016/j.jacc.2003.12.040
46. Sanam K, Bhatia V, Bajaj NS, et al. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure. Am J Med. Oct 2016;129(10):1067-73. doi:10.1016/j.amjmed.2016.05.008
47. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. Feb 7 2019;380(6):539-548. doi:10.1056/NEJMoa1812851
48. Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. Aug 2019;21(8):998-1007. doi:10.1002/ejhf.1498
49. Berg DD, Braunwald E, DeVore AD, et al. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail. Oct 2020;8(10):834-843. doi:10.1016/j.jchf.2020.06.008
50. Fonarow GC, Abraham WT, Albert NM, et al. Prospective Evaluation of Beta-Blocker Use at the Time of Hospital Discharge as a Heart Failure Performance Measure: Results From OPTIMIZE-HF. Journal of Cardiac Failure. 2007;13(9):722-731. doi:10.1016/j.cardfail.2007.06.727
51. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. Jul 15 2008;52(3):190-9. doi:10.1016/j.jacc.2008.03.048
52. Lee KK, Yang J, Hernandez AF, Steimle AE, Go AS. Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. Med Care. Apr 2016;54(4):365-72. doi:10.1097/mlr.0000000000000492
53. McAlister FA, Youngson E, Kaul P, Ezekowitz JA. Early Follow-Up After a Heart Failure Exacerbation: The Importance of Continuity. Circ Heart Fail. Sep 2016;9(9)doi:10.1161/circheartfailure.116.003194
54. Savarese G, Lund LH, Dahlström U, Strömberg A. Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization. J Am Heart Assoc. May 21 2019;8(10):e011737. doi:10.1161/jaha.118.011737
55. Logeart D, Berthelot E, Bihry N, et al. Early and short-term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD-HF). European Journal of Heart Failure. 2022;24(1):219-226. doi:https://doi.org/10.1002/ejhf.2357
56. Savarese G, Kishi T, Vardeny O, et al. HeartFailure Drug Treatment-Inertia,Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC: Heart Failure. 2023/01/01/ 2023;11(1):1-14. doi:https://doi.org/10.1016/j.jchf.2022.08.009
57. Tomasoni D, Pagnesi M, Colombo G, et al. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Eur J Heart Fail. Feb 2024;26(2):327-337. doi:10.1002/ejhf.3081
58. Seferović PM, Polovina M, Adlbrecht C, et al. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. Eur J Heart Fail. Dec 2021;23(12):1999-2007. doi:10.1002/ejhf.2378
59. Khan MS, Segar MW, Usman MS, et al. Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial. JACC Heart Fail. Apr 2022;10(4):266-275. doi:10.1016/j.jchf.2021.12.004
60. Arrigo M, Biegus J, Asakage A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: A sub-analysis of the STRONG-HF randomized clinical trial. Eur J Heart Fail. Jul 2023;25(7):1145-1155. doi:10.1002/ejhf.2920
61. Savarese G, Lindberg F, Christodorescu RM, et al. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice. European Journal of Heart Failure. 2024;26(6):1408-1418. doi:https://doi.org/10.1002/ejhf.3214
62. Jalloh MB, Granger CB, Fonarow GC, Van Spall HGC. Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure. Eur Heart J. Jun 20 2023;44(23):2055-2058. doi:10.1093/eurheartj/ehad150
63. van der Wal MH, Jaarsma T, van Veldhuisen DJ. Non-compliance in patients with heart failure; how can we manage it? Eur J Heart Fail. Jan 2005;7(1):5-17. doi:10.1016/j.ejheart.2004.04.007
64. Jonkman NH, Westland H, Groenwold RH, et al. What Are Effective Program Characteristics of Self-Management Interventions in Patients With Heart Failure? An Individual Patient Data Meta-analysis. J Card Fail. Nov 2016;22(11):861-871. doi:10.1016/j.cardfail.2016.06.422
65. Unverzagt S, Meyer G, Mittmann S, Samos FA, Unverzagt M, Prondzinsky R. Improving Treatment Adherence in Heart Failure. Dtsch Arztebl Int. Jun 24 2016;113(25):423-30. doi:10.3238/arztebl.2016.0423
66. Wang L, Zhao Y, Han L, et al. Pharmacist-Led Management Model and Medication Adherence Among Patients With Chronic Heart Failure: A Randomized Clinical Trial. JAMA Netw Open. Dec 2 2024;7(12):e2453976. doi:10.1001/jamanetworkopen.2024.53976
67. Goldstein CM, Gathright EC, Dolansky MA, et al. Randomized controlled feasibility trial of two telemedicine medication reminder systems for older adults with heart failure. J Telemed Telecare. Sep 2014;20(6):293-9. doi:10.1177/1357633x14541039
68. Stolfo D, Iacoviello M, Chioncel O, et al. How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. European Journal of Heart Failure. n/a(n/a)doi:https://doi.org/10.1002/ejhf.3642
69. Pandey A, Keshvani N, Wang TJ. Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction? Circulation. 2022;146(4):276-278. doi:doi:10.1161/CIRCULATIONAHA.122.059661
70. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta-Analysis of Controlled Trials. J Am Heart Assoc. Jun 17 2016;5(6)doi:10.1161/jaha.115.002606
71. Tomasoni D, Vitale C, Guidetti F, et al. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. Apr 2024;26(4):854-868. doi:10.1002/ejhf.3112
72. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: A systematic review and meta-analysis. Int J Cardiol. Jun 1 2017;236:283-289. doi:10.1016/j.ijcard.2017.01.153
73. Seferović PM, Piepoli MF, Lopatin Y, et al. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. Eur J Heart Fail. May 2020;22(5):763-774. doi:10.1002/ejhf.1784
74. Bonilla-Palomas JL, Gámez-López AL, Castillo-Domínguez JC, et al. Nutritional Intervention in Malnourished Hospitalized Patients with Heart Failure. Archives of Medical Research. 2016/10/01/ 2016;47(7):535-540. doi:https://doi.org/10.1016/j.arcmed.2016.11.005
75. Holland R, Battersby J, Harvey I, Lenaghan E, Smith J, Hay L. Systematic review of multidisciplinary interventions in heart failure. Heart. Jul 2005;91(7):899-906. doi:10.1136/hrt.2004.048389
76. Kitzman DW, Whellan DJ, Duncan P, et al. Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. N Engl J Med. Jul 15 2021;385(3):203-216. doi:10.1056/NEJMoa2026141
77. Nadruz W, Jr., West E, Sengeløv M, et al. Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. J Am Heart Assoc. Oct 31 2017;6(11)doi:10.1161/jaha.117.006000
78. Swank AM, Horton J, Fleg JL, et al. Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. Circ Heart Fail. Sep 1 2012;5(5):579-85. doi:10.1161/circheartfailure.111.965186
79. Resurrección DM, Moreno-Peral P, Gómez-Herranz M, et al. Factors associated with non-participation in and dropout from cardiac rehabilitation programmes: a systematic review of prospective cohort studies. Eur J Cardiovasc Nurs. Jan 2019;18(1):38-47. doi:10.1177/1474515118783157
80. Lee CS, Bidwell JT, Paturzo M, et al. Patterns of self-care and clinical events in a cohort of adults with heart failure: 1 year follow-up. Heart Lung. Jan-Feb 2018;47(1):40-46. doi:10.1016/j.hrtlng.2017.09.004
81. Jaarsma T, Hill L, Bayes-Genis A, et al. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. Jan 2021;23(1):157-174. doi:10.1002/ejhf.2008
82. Park JJ, Kim S-H, Oh I-Y, et al. The Effect of Door-to-Diuretic Time on Clinical Outcomes in PatientsWithAcute Heart Failure. JACC: Heart Failure. 2018;6(4):286-294. doi:doi:10.1016/j.jchf.2017.12.017
83. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. Mar 3 2011;364(9):797-805. doi:10.1056/NEJMoa1005419
84. Butler J, Anstrom KJ, Felker GM, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol. Sep 1 2017;2(9):950-958. doi:10.1001/jamacardio.2017.2198
85. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome Trial. JAMA. 2007;297(12):1319-1331. doi:10.1001/jama.297.12.1319
86. Costanzo MR, Ronco C, Abraham WT, et al. Extracorporeal Ultrafiltration for FluidOverload in Heart Failure: Current Status and Prospects for Further Research. Journal of the American College of Cardiology. 2017/05/16/ 2017;69(19):2428-2445. doi:https://doi.org/10.1016/j.jacc.2017.03.528
87. Bhatt AS, Varshney AS, Moscone A, et al. Virtual Care Team Guided Management of Patients With Heart Failure DuringHospitalization. J Am Coll Cardiol. May 2 2023;81(17):1680-1693. doi:10.1016/j.jacc.2023.02.029
88. Rao VN, Shah A, McDermott J, et al. In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial. Circ Heart Fail. Feb 2023;16(2):e010158. doi:10.1161/circheartfailure.122.010158
89. Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. Sep 22 2018;392(10152):1047-1057. doi:10.1016/s0140-6736(18)31880-4
90. Wong CK, Un KC, Zhou M, et al. Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study. Eur Heart J Digit Health. Jun 2022;3(2):284-295. doi:10.1093/ehjdh/ztac024
91. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. Jun 24 2023;401(10394):2113-2123. doi:10.1016/s0140-6736(23)00923-6
92. Ghazi L, Yamamoto Y, Riello RJ, et al. Electronic Alerts to Improve HeartFailure Therapy in Outpatient Practice: AClusterRandomized Trial. J Am Coll Cardiol. Jun 7 2022;79(22):2203-2213. doi:10.1016/j.jacc.2022.03.338
93. Allen LA, Venechuk G, McIlvennan CK, et al. An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial. Circulation. Feb 2 2021;143(5):427-437. doi:10.1161/circulationaha.120.051863
94. Janse RJ, Fu EL, Dahlström U, et al. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence. European Journal of Heart Failure. 2022;24(11):2185-2195. doi:https://doi.org/10.1002/ejhf.2620
95. Granger BB, Ekman I, Granger CB, et al. Adherence to medication according to sex and age in the CHARM programme. European Journal of Heart Failure. 2009;11(11):1092-1098. doi:https://doi.org/10.1093/eurjhf/hfp142
96. Aggarwal B, Pender A, Mosca L, Mochari-Greenberger H. Factors associated with medication adherence among heart failure patients and their caregivers. J Nurs Educ Pract. 2015;5(3):22-27. doi:10.5430/jnep.v5n3p22
97. Gunnthorsdottir I, Almarsdottir AB, Andersen K, et al. Factors Influencing Medication Adherence in Heart Failure Patients—A Survey Among Cardiac Healthcare Providers. Clinical Pharmacology & Therapeutics. 2025;117(4):1088-1097. doi:https://doi.org/10.1002/cpt.3526